Loss of FASN rendered cancer cells more susceptible to killing by an in vitro model of adoptive T-cell therapy (ACP), cytokine-induced non-MHC-restricted CAT cells [39–44], suggesting that antigen-specific tumor recognition by T cells is dispensable for the ability of FASN blockade to enhance the in vitro efficacy of ACP even at low (0.5:1), physiologically and therapeutically relevant effector-to-target ratios. This evidence concerns the gene FASN and cancer.